Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, van Werkhoven E, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Among authors: ten tije aj. Eur J Cancer. 2019 Jan;107:60-67. doi: 10.1016/j.ejca.2018.11.010. Epub 2018 Dec 11. Eur J Cancer. 2019. PMID: 30544060
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. Henricks LM, et al. Among authors: ten tije aj. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348537
Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
Franken MD, van Rooijen EM, May AM, Koffijberg H, van Tinteren H, Mol L, Ten Tije AJ, Creemers GJ, van der Velden AMT, Tanis BC, Uyl-de Groot CA, Punt CJA, Koopman M, van Oijen MGH. Franken MD, et al. Among authors: ten tije aj. Eur J Cancer. 2017 Apr;75:204-212. doi: 10.1016/j.ejca.2017.01.019. Epub 2017 Feb 24. Eur J Cancer. 2017. PMID: 28237866 Clinical Trial.
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R. Meulenbeld HJ, et al. Among authors: ten tije aj. Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6. Eur J Cancer. 2012. PMID: 22677260 Free article. Clinical Trial.
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H. Wissing MD, et al. Among authors: ten tije aj. Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3. Int J Cancer. 2015. PMID: 25242736
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Simkens LH, et al. Among authors: ten tije aj. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7. Lancet. 2015. PMID: 25862517 Clinical Trial.
A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
Drooger JC, van Tinteren H, de Groot SM, Ten Tije AJ, de Graaf H, Portielje JE, Jager A, Honkoop A, Linn SC, Kroep JR, Erdkamp FL, Hamberg P, Imholz AL, van Rossum-Schornagel QC, Heijns JB, van Leeuwen-Stok AE, Sleijfer S. Drooger JC, et al. Among authors: ten tije aj. Cancer. 2016 Oct;122(19):2961-70. doi: 10.1002/cncr.30141. Epub 2016 Jun 17. Cancer. 2016. PMID: 27315546 Free article. Clinical Trial.
Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Devilee RA, Simkens GA, van Oudheusden TR, Rutten HJ, Creemers GJ, Ten Tije AJ, de Hingh IH. Devilee RA, et al. Among authors: ten tije aj. Ann Surg Oncol. 2016 Sep;23(9):2841-8. doi: 10.1245/s10434-016-5214-3. Epub 2016 Apr 4. Ann Surg Oncol. 2016. PMID: 27044447
Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group.
Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJM, Hendriks MP, Los M, van Alphen RJ, Polée MB, Muller EW, van der Velden AMT, van Voorthuizen T, Koopman M, Mol L, van Werkhoven E, Punt CJA. Kwakman JJM, et al. Among authors: ten tije aj. Ann Oncol. 2017 Jun 1;28(6):1288-1293. doi: 10.1093/annonc/mdx122. Ann Oncol. 2017. PMID: 28383633 Free article. Clinical Trial.
97 results